Contact
Solutions
Establishing A Strategy
Target Product Profile
Global Regulatory Strategy
Integrated Product Development
Paediatric Strategy
Orphan Designation
Non-Clinical and Quality
Cell Line Development and Vector Selection
Characterization
Safety Assessment
Selection of In-Vivo and In-Vitro Models
Power Of Data Science
Raw Material Assessment
Biosimilarity Assessment
Quality Management and Compliance
Regulatory Agency Interactions and Clinical Trials
Accelerated Programs
Regulatory Agency Interactions
Executing the Clinical Program
Pharmacovigilance
Marketing Authorization
Due Diligence and Partnering
Product Types
Vaccines
Insights
Case Studies
White Papers
Blog
Articles
Videos
Newsletters
Science Huddle
About Us
Corporate Social Responsibility
About PharmaLex
News & Events
Events
Press Releases
Contact Us
Home
Insights
Insights
Enter keywords below to search for the most relevant scientific insights for you.
Filter Results
Date
From
To
Content Type
White Papers
Case Studies
Blog
Articles
Newsletters
Videos
Podcasts
Science Huddle
Reset
Blog
Planning for CBER and EMA success with cell and gene therapy
28.03.23
By
Cori Gorman, Ph.D.
By Cori Gorman, Ph.D. The fields of cell and gene therapy are enormously promising while
Read More
Blog
Insights into issues and developments from Advanced Therapies Week
22.03.23
By
Dr. Jörg Schneider
Dr. Jörg Schneider, Director – Principal Consultant at BioPharma Excellence, shares key takeaways from Advanced
Read More
Case Study
Early phase modelling establishes opportunities and feasibility of ATMP for rare genetic disorder
3.02.23
A project consortium was launching an EU-funded clinical trial for a first-in-class advanced therapeutic medicinal
Read More
Blog
ICH’s viral safety guidelines catch up with the latest biotech innovations
1.02.23
By
Sebastian Teitz, Ph.D
More than 25 years after adopting the first version of the guideline on the viral
Read More
White Paper
Science Huddle – SMALL DATA, BIG OUTCOMES
26.01.23
With the reach and impact of biopharma growing exponentially, experts in biotech and the evolving
Read More
Blog
The rise of Bayesian statistics in rare disease evidence gathering
16.01.23
Regulators are becoming more open to alternative data sources in the context of rare disease
Read More
1
2
3
Next